Clinical trial
Aprospective, Multi Center Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, an Anti-her2-antibody Drug Conjugate in Indian Patients With Unresectable or Metastatic her2-positive Breast Cancer Who Have Received a Prior Anti-her2-based Regimen
NCT06429761 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aprospective, Multi Center Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, an Anti-her2-antibody Drug Conjugate in Indian Patients With Unresectable or Metastatic her2-positive Breast Cancer Who Have Received a Prior Anti-her2-based Regimen
- Lead sponsor
- AstraZeneca
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- January 2, 2025
- Completion date
- October 31, 2026
- Enrollment
- 100 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer